The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | A new first-line standard for elderly CLL with single-agent ibrutinib?
Jennifer Woyach, MD, of the Ohio State University College of Medicine, Columbus, OH, talks to use about the Phase III ALLIANCE A041202 trial (NCT01886872), which compared bendamustine plus rituximab (BR), ibrutinib, and ibrutinib plus rituximab. Dr Woyach highlights the progression-free survival results, which were superior in the ibrutinib arm vs. the BR arm, while the addition of rituximab to ibrutinib had no significant benefit. This interview took place at the the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
